Effect of squill oxymel in control of mild to moderate fatty liver

therapeutic Effect and safety of squill oxymel in control of fatty liver disease in patients with mild to moderate fatty liver

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201705261165N20

Enrollment

150

Registered

2017-07-23

Start date

2017-04-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fatty liver. k75.8

Interventions

Intervention 1: intervention:squill oxymel,scientific name:drimia maritima. each 5 ml contains 25 mg of squill. dose of consumption:30 ml daily (orally).devided 3 times a day. duration of consumption:

Treatment - Drugs

Placebo

intervention:squill oxymel,scientific name:drimia maritima. each 5 ml contains 25 mg of squill. dose of consumption:30 ml daily (orally).devided 3 times a day. duration of consumption:2 month. gor

control:placebo oxymel,15 cc daily,until 2 month

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: To Sign the consent form Knowingly patients be suffered from mild to moderate fatty liver According to the ultrasound result. Exclusion criteria: Off treatment for more than a week Progression of Fatty liver disease Person is pregnant or lactating Allergic reactions to herbal blend

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Improvment of quality of life. Timepoint: at baseline and 2 month after intervention. Method of measurement: quality of life questionnaire.;FBS. Timepoint: at baseline and 2 month after intervention. Method of measurement: mg/dl.;Triglycerides. Timepoint: at baseline and 2 month after intervention. Method of measurement: mg/dl.;Cholesterol. Timepoint: at baseline and 2 month after intervention. Method of measurement: mg/dl.;Hdl. Timepoint: at baseline and 2 month after intervention. Method of measurement: mg/dl.;Ldl. Timepoint: at baseline and 2 month after intervention. Method of measurement: mg/dl.;Alt. Timepoint: at baseline and 2 month after intervention. Method of measurement: iu/l.;Ast. Timepoint: at baseline and 2 month after intervention. Method of measurement: iu/l.;Alp. Timepoint: at baseline and 2 month after intervention. Method of measurement: iu/l.;Grade of fatty liver. Timepoint: at baseline and 2 month after intervention. Method of measurement: sonography.	—

Measure

Time frame

Improvment of quality of life. Timepoint: at baseline and 2 month after intervention. Method of measurement: quality of life questionnaire.;FBS. Timepoint: at baseline and 2 month after intervention. Method of measurement: mg/dl.;Triglycerides. Timepoint: at baseline and 2 month after intervention. Method of measurement: mg/dl.;Cholesterol. Timepoint: at baseline and 2 month after intervention. Method of measurement: mg/dl.;Hdl. Timepoint: at baseline and 2 month after intervention. Method of measurement: mg/dl.;Ldl. Timepoint: at baseline and 2 month after intervention. Method of measurement: mg/dl.;Alt. Timepoint: at baseline and 2 month after intervention. Method of measurement: iu/l.;Ast. Timepoint: at baseline and 2 month after intervention. Method of measurement: iu/l.;Alp. Timepoint: at baseline and 2 month after intervention. Method of measurement: iu/l.;Grade of fatty liver. Timepoint: at baseline and 2 month after intervention. Method of measurement: sonography.

—

Secondary

Measure	Time frame
Bmi. Timepoint: at baseline and 2 month after intervention. Method of measurement: kg/m2.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactfateme hadei

pharmaceutical sciences branch islamic azad university

yunespanahi@yahoo.com+98 21 8821 1524

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026